Jonathan Yen-Wen Yu Sells 9,700 Shares of Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 9,700 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $72.66, for a total transaction of $704,802.00. Following the transaction, the chief operating officer owned 54,324 shares of the company’s stock, valued at approximately $3,947,181.84. The trade was a 15.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Jonathan Yen-Wen Yu also recently made the following trade(s):

• On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The shares were sold at an average price of $69.19, for a total transaction of $1,287,764.28.

Disc Medicine Trading Up 0.0%

Shares of IRON traded up $0.02 during trading hours on Wednesday, hitting $70.47. 1,220,498 shares of the stock were exchanged, compared to its average volume of 485,366. Disc Medicine, Inc. has a fifty-two week low of $40.00 and a fifty-two week high of $99.50. The business has a 50-day moving average of $68.80 and a 200-day moving average of $71.18. The firm has a market capitalization of $2.69 billion, a P/E ratio of -10.64 and a beta of 0.93. The company has a debt-to-equity ratio of 0.04, a current ratio of 24.00 and a quick ratio of 24.00.

Disc Medicine (NASDAQ:IRON) last released its earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.62) by ($0.03). On average, research analysts expect that Disc Medicine, Inc. will post -6.74 EPS for the current year.

Wall Street Analysts Forecast Growth

IRON has been the topic of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a research report on Monday, April 20th. Wells Fargo & Company boosted their price target on Disc Medicine from $78.00 to $79.00 and gave the company an “overweight” rating in a research note on Monday, March 2nd. Wall Street Zen upgraded Disc Medicine from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Truist Financial reduced their price objective on shares of Disc Medicine from $114.00 to $83.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Finally, Wedbush reiterated an “outperform” rating and issued a $88.00 price objective on shares of Disc Medicine in a research note on Wednesday, June 10th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $105.80.

Institutional Trading of Disc Medicine

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. RA Capital Management L.P. boosted its position in shares of Disc Medicine by 25.3% during the fourth quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock valued at $156,925,000 after buying an additional 399,026 shares during the last quarter. Vanguard Group Inc. raised its position in Disc Medicine by 22.1% in the 4th quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company’s stock valued at $140,371,000 after buying an additional 319,621 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Disc Medicine by 28.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,698,005 shares of the company’s stock valued at $134,839,000 after acquiring an additional 371,576 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Disc Medicine by 110.0% during the 4th quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock valued at $125,557,000 after acquiring an additional 828,248 shares in the last quarter. Finally, Wellington Management Group LLP boosted its holdings in Disc Medicine by 7.7% during the 4th quarter. Wellington Management Group LLP now owns 1,518,274 shares of the company’s stock worth $120,566,000 after acquiring an additional 108,197 shares during the last quarter. 83.70% of the stock is owned by institutional investors.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.